Evidence map›Paper›PMID 33579042›Full record

ArticleTropical medicine and infectious disease2021

SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.

Sarah Cristina Gozzi-Silva, Gil Benard, Ricardo Wesley Alberca, Tatiana Mina Yendo, Franciane Mouradian Emidio Teixeira, Luana de Mendonça Oliveira, Danielle Rosa Beserra, Anna Julia Pietrobon, Emily Araujo de Oliveira, Anna Cláudia Calvielli Castelo Branco and 9 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Tropical medicine and infectious disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. COVID-19: Current Challenges and Future Perspectives.Tropical medicine and infectious disease · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Sarah Cristina Gozzi-SilvaLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Gil BenardLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Ricardo Wesley AlbercaLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Tatiana Mina YendoLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Franciane Mouradian Emidio TeixeiraLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.ORCID 0000-0001-5622-903X
Luana de Mendonça OliveiraLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Danielle Rosa BeserraLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Anna Julia PietrobonLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Emily Araujo de OliveiraLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Anna Cláudia Calvielli Castelo BrancoLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Milena Mary de Souza AndradeLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Iara Grigoletto FernandesLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Nátalli Zanete PereiraLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Yasmim Álefe Leuzzi RamosLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Julia Cataldo LimaLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Bruna ProvenciInstituto do Coração (Incor), Hospital das Clínicas, School of Medicine of University of São Paulo (HCFMUSP), 05403-900 São Paulo, Brazil.
Sandrigo ManginiInstituto do Coração (Incor), Hospital das Clínicas, School of Medicine of University of São Paulo (HCFMUSP), 05403-900 São Paulo, Brazil.
Alberto José da Silva DuarteLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Maria Notomi SatoLaboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.ORCID 0000-0002-7911-1824
Universidade de São Paulo · BRHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BR

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 88887.503842/2020-00Fundação de Amparo à Pesquisa do Estado de São Paulo 19/02679-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/18230-6Fundação de Amparo à Pesquisa do Estado de São Paulo 2019/22448-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2019/26928-6
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a pandemic. SARS-CoV-2 infection can lead to severe pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and/or organ failure. Individuals receiving a heart transplantation (HT) may be at higher risk of adverse outcomes attributable to COVID-19 due to immunosuppressives, as well as concomitant infections that may also influence the prognoses. Herein, we describe the first report of two cases of HT recipients with concomitant infections by SARS-CoV-2,

Indexed as

Chagas diseaseCMVCOVID-19heart transplantinfectionSARS-CoV-2severity

Identifiers

PMID33579042
PMCPMC7985779
OpenAlexW3126845200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.